Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CervoMed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CervoMed's regulatory disclosures and financial reporting.
CervoMed Inc. reported a Form 4 showing that Matthew Winton, serving as Chief Commercial and Business Officer and a director-level officer, received a grant of 75,000 stock options as an inducement award tied to his employment. The options have an exercise price of $8.62 and were issued with an acquisition date of 10/06/2025. The award vests in equal monthly installments over 36 months, beginning on 10/31/2025, and the option term extends to 10/06/2035. The filing was signed on 10/07/2025.
CervoMed Inc. (CRVO) filed an initial Form 3 reporting that Matthew Winton, identified as an officer (Chief Commercial and Business), does not beneficially own any securities of the company as of the event date 10/06/2025. The filing lists Winton's business address in Boston and is signed by the reporting person. No derivative or non-derivative holdings are disclosed.
CervoMed Inc. (CRVO) received an amended Schedule 13G/A from RA Capital entities and two individuals correcting a prior filing to report warrants and resulting beneficial ownership as of June 30, 2025. The amendment discloses that RA Capital Healthcare Fund, L.P. holds warrants exercisable for up to 1,266,143 shares, but a contractual "Beneficial Ownership Blocker" limits exercise so the Fund and affiliated reporting persons may not beneficially own more than 9.99% of CervoMed's common stock. As corrected, each reporting person is shown as beneficially owning 1,026,937 shares, representing 9.99% (rounded to 9.9% on cover pages) based on 9,252,719 shares outstanding plus issuable upon exercise. The filing states the prior omission was a clerical error and disclaims group status and broader beneficial ownership except for Section 13(d) purposes.
CervoMed Inc. Schedule 13G/A filed by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah reports that each Reporting Person holds zero shares of CervoMed common stock representing 0.0% of the class as shown on the cover pages. The filers state they are not acting as a group and that the securities were not acquired to influence control of the issuer. The principal business address for the Reporting Persons is c/o RA Capital Management, L.P., Boston, MA.
CervoMed Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into Item 2.02, and the filing states that the information is being furnished under Item 2.02 rather than filed for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 (the press release) and 104 (cover page interactive data file).
CervoMed (CRVO) 10-Q, Q2-25: The neuro-focused biotech remains pre-commercial and relies on NIA grant income. Q2 grant revenue fell 46% YoY to $1.76 million as RewinD-LB funding winds down, while R&D expense rose 35% to $5.1 million and G&A climbed 30% to $3.3 million. Operating loss therefore more than doubled to $6.6 million; net loss was $6.3 million (-$0.70/sh) versus $2.3 million (-$0.27/sh) a year earlier. For the six-month period, revenue dropped 35% to $3.7 million and net loss widened to $11.2 million.
Cash & cash equivalents were $8.3 million and marketable securities $25.2 million, giving $33.5 million of liquid resources versus $38.9 million at year-end. Operating cash burn reached $10.4 million YTD, partially offset by $4.6 million raised via a May 2025 at-the-market sale of 550k shares. Management believes current funds plus remaining $2.9 million of NIA grant receivables support operations for “at least” 12 months but acknowledges the need for additional capital to advance lead asset neflamapimod beyond ongoing Phase 2 programs. Shares outstanding rose to 9.25 million.
CervoMed (NASDAQ:CRVO) filed an 8-K (Item 5.07) reporting voting results from its June 23 2025 Annual Meeting.
With 64.5% of shares represented, stockholders approved all four proposals: (1) election of seven directors; (2) ratification of RSM US LLP as 2025 auditor (5,571,505 for, 25,008 against); (3) advisory endorsement of 2024 executive pay (3,891,229 for, 33,195 against); and (4) adoption of the 2025 Equity Incentive Plan (3,798,568 for, 137,758 against). No other material changes, governance shifts, or financial impacts were disclosed.